Is it time for personalized therapy in IgA nephropathy patients?

Excerpt

Roccatello et al. [1] investigated the effectiveness and safety of mycophenolate mofetil (MMF) in combination with corticosteroids, compared to a 6-month course of glucocorticoids alone, in a group of 30 patients with proteinuric immunoglobulin A nephropathy (IgAN) who had active renal lesions (including proliferative endocapillary and extracapillary lesions and fibrinoid necrosis) identified through kidney biopsy. All patients received renin-angiotensin system blockers (RASBs) at the maximum tolerated dose as supportive therapy. The retrospective study demonstrated a significant reduction in proteinuria in both patient groups, with the mean follow-up period being 18.7 months for the first group receiving MMF in combination with corticosteroids, and 21.5 months for the group treated with corticosteroids alone. At the end of the follow-up period, the authors obtained a cumulative sparing dose of 6 g of corticosteroids in the group of patients who received the combined therapy (MMF and corticosteroids). …